Research programme: cytomegalovirus vector based immunotherapeutics - UbiVac

Drug Profile

Research programme: cytomegalovirus vector based immunotherapeutics - UbiVac

Alternative Names: CMV replication deficient vaccine - UbiVac; sdCMV 001; sdCMV 002

Latest Information Update: 12 Sep 2016

Price : $50

At a glance

  • Originator UbiVac
  • Developer Oregon Health & Science University; UbiVac
  • Class Cancer vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Human papillomavirus infections; Malignant melanoma

Most Recent Events

  • 28 Oct 2015 Preclinical trials in Cancer in USA (parenteral) before October 2015 (UbiVac pipeline, October 2015)
  • 28 Oct 2015 Preclinical trials in Human papillomavirus infections in USA (parenteral) (UbiVac pipeline, October 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top